This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
Burden of Disease
Burden of Disease
Risk Factors
Secondary Infections
Mechanism of Action
Prevention of Pneumococcal Disease
Need for Pneumococcal Vaccination
Cost-effectiveness of PCV13
Legacy of Prevenar
Safety
Conclusion
Dosing
Prevenar 13® Clinical Experience
Efficacy of Prevenar 13®
Effectiveness of Prevenar 13®
Indian Clinical Trials
Recommendations for Use
PCV13 in Pulmonology
PCV13 in Nephrology
PCV13 in Oncology
PCV13 in Rheumatology
PCV13 in Diabetes
PCV13 in HIV Infection
PCV13 in Cardiology
Resources
Clinical and Immunogenicity Data of Pneumococcal Vaccines in Patients With Cardiovascular Diseases
Apart from reducing the incidence of pneumonia, pneumococcal vaccinations have been implicated in lowering CV morbidity and mortality in the elderly population. Therefore, available data suggest the use of vaccination in the HF population.1 Although there is scarcity of randomised controlled trial evidence on the safety and efficacy of pneumococcal vaccines in CV events, it has been suggested that these vaccines may have a protective effect in patients with HF.2
Tseng et al. performed a retrospective cohort study on older patients aged ≥65 years, vaccinated either with PPSV23 or PCV13, to compare the risk of adverse events following vaccination. The prespecified adverse events studied included CV events. The total number of doses of PCV13 and PPSV23 included in the study were 3,13,136 and 2,32,591, respectively. The study reported no increased rate of adverse events with PCV13 use, as compared with PPSV23, and provided reassurance regarding continuous use of PCV13 in this group of adults.3
Using a test-negative design, McLaughlin et al. performed a real-world study to evaluate the effectiveness of PCV13 against hospitalisation for CAP in older US adults aged ≥65 years. The study included a high-risk group of patients, including those with congestive heart failure (31.9%). The estimated vaccine effectiveness of PCV13 in the risk group of patients was 73.3 for all VT-CAP and 70.7 for non-bacteraemic VT-CAP. Therefore, the study reassured the effectiveness of PCV13 against VT-CAP in elderly patients with congestive HF.4
CAP, community-acquired pneumonia; CV, cardiovascular; HF, heart failure; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal plain polysaccharide vaccine; VT-CAP, vaccine-type community-acquired pneumonia.
References:
Please click the Prescribing Information link to view the safety and adverse events information of Prevenar 13®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-PRV-IND-0268 July 2022
Help protect your adult patients against pneumococcal pneumonia with single-dose administration
Learn more
Efficacy proven by the CAPiTA study
Learn more
The ACIP recommends routine use of PCV13 among adults
Learn more
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.